Publicaciones en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (54)

2024

  1. Sprouty1 is a broad mediator of cellular senescence

    Cell Death and Disease, Vol. 15, Núm. 4

2020

  1. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma

    Journal of Investigative Dermatology, Vol. 140, Núm. 6, pp. 1253-1265

2019

  1. Cytoplasmic cyclin D1 regulates glioblastoma dissemination

    Journal of Pathology, Vol. 248, Núm. 4, pp. 501-513

  2. Tumor suppressive function of E2F-1 on PTEN-induced serrated colorectal carcinogenesis

    Journal of Pathology, Vol. 247, Núm. 1, pp. 72-85

2017

  1. Endometrial carcinoma: Specific targeted pathways

    Advances in Experimental Medicine and Biology (Springer New York LLC), pp. 149-207

2016

  1. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels

    Pigment Cell and Melanoma Research, Vol. 29, Núm. 3, pp. 352-371

  2. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer

    Molecular Imaging and Biology, Vol. 18, Núm. 4, pp. 545-556

  3. Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer

    Oncotarget, Vol. 7, Núm. 19, pp. 26979-26991

2015

  1. Impaired Vitamin D signaling in endothelial cell leads to an enhanced leukocyte-endothelium interplay: Implications for atherosclerosis development

    PLoS ONE, Vol. 10, Núm. 8

  2. Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: Endometrial cancer as a model

    Methods, Vol. 77, pp. 31-40

2014

  1. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry

    Human Pathology, Vol. 45, Núm. 12, pp. 2394-2403

  2. Combinatorial therapy using dovitinib and ICI182.780 (Fulvestrant) blocks tumoral activity of endometrial cancer cells

    Molecular Cancer Therapeutics, Vol. 13, Núm. 4, pp. 776-787

  3. FISH analysis of PTEN in endometrial carcinoma: Comparison with SNP arrays and MLPA

    Histopathology, Vol. 65, Núm. 3, pp. 371-388

  4. Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma

    Laboratory Investigation, Vol. 94, Núm. 6, pp. 608-622

2013

  1. Endometrial carcinoma: Molecular alterations involved in tumor development and progression

    Oncogene, Vol. 32, Núm. 4, pp. 403-413

  2. Epithelial-to-mesenchymal transition and stem cells in endometrial cancer

    Human Pathology, Vol. 44, Núm. 10, pp. 1973-1981

  3. Three-dimensional epithelial cultures: A tool to model cancer development and progression

    Histology and Histopathology, Vol. 28, Núm. 10, pp. 1245-1256

2012

  1. Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

    Molecular Oncology, Vol. 6, Núm. 5, pp. 530-541

  2. ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a crucial role for TNFα and IL1α in lumen formation and maintenance

    Journal of Cell Science, Vol. 125, Núm. 8, pp. 1929-1944

  3. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma

    Human Pathology, Vol. 43, Núm. 5, pp. 632-643